TORNTPHARM4,925.00

Torrent Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMAJBCHEPHARMMANKINDZYDUSLIFEDIVISLABMAXHEALTHDRREDDYCIPLAMcap ₹1.67L Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.700.710.740.75
Interest Burden (Pretax/EBIT) ×0.920.910.830.78
EBIT Margin %23.8625.4124.6123.41
Asset Turnover ×0.710.770.320.32
Financial Leverage (Assets/Equity) ×2.201.972.522.52
ROE (5-step product) %24.0825.2312.3311.06
ROE (reported, avg-equity basis) %24.1525.1712.3012.30
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.